Compare Norfolk Southern Corporation (NSC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Viatris Inc — how do they compare? Norfolk Southern Corporation trades at $335.65 (market cap $75.15B), while Viatris Inc trades at $16.26 (market cap $18.69B). The key difference: Norfolk Southern Corporation is far larger — about 4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| NSC | VTRS | |
|---|---|---|
Market Cap | $75.15B | $18.69B |
Sector | Technology | Health |
52-Week High | $350.66 | $17.86 |
52-Week Low | $272.35 | $9.49 |
Enterprise Value | $90.70B | $30.80B |
Dividend Yield | 1.61% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $332.82, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $3.52 per share, beating estimates, driven by record revenue and volume growth. Valuation ratios like P/E of 28.55 and P/S of 5.99 indicate a premium, while profitability remains solid with a net income margin of 21.02% and ROE of 16.97%. Recent news highlights merger developments with Union Pacific and institutional interest.
Outlook is cautiously optimistic due to earnings momentum and industry tailwinds, but risks include high fuel costs, merger execution uncertainties, and premium valuation. Analysts give a mixed consensus with 43.75% buy ratings and a $369.67 price target, suggesting modest upside potential from current levels amid competitive and operational headwinds.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
